Dosing & Uses
Dosage Forms & Strengths
tablet
- 500mg
Elevated Urinary pH
1-2 tabs (500-1000mg) dissolved in 6-8 oz of water; take PO four times daily with meals and at bedtime
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (9)
- amiloride
amiloride and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.
- drospirenone
drospirenone and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.
- eplerenone
potassium acid phosphate, eplerenone. Mechanism: pharmacodynamic synergism. Contraindicated. Hyperkalemia.
- erdafitinib
potassium acid phosphate, erdafitinib. Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid coadministration during initial dosing adjustment period (ie, first 21 days). Increases in serum phosphate levels are a pharmacodynamic effect of FGFR inhibition. Serum phosphate binders may obscure decisions regarding initial dosage increase.
- potassium chloride
potassium acid phosphate and potassium chloride both increase serum potassium. Avoid or Use Alternate Drug.
- potassium citrate
potassium acid phosphate and potassium citrate both increase serum potassium. Avoid or Use Alternate Drug.
- potassium phosphates, IV
potassium acid phosphate and potassium phosphates, IV both increase serum potassium. Avoid or Use Alternate Drug.
- spironolactone
spironolactone and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.
- triamterene
triamterene and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.
Monitor Closely (107)
- acebutolol
acebutolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- aceclofenac
aceclofenac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- acemetacin
acemetacin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- albuterol
potassium acid phosphate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- arformoterol
potassium acid phosphate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- aspirin
aspirin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- aspirin rectal
aspirin rectal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- atenolol
atenolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- benazepril
benazepril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
potassium acid phosphate and benazepril both increase serum potassium. Use Caution/Monitor. Potassium salts may increase the hyperkalemic effects of ACE inhibitors; the effect may be the result of aldosterone suppression in patients receiving ACE inhibitors - bendroflumethiazide
potassium acid phosphate increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- betaxolol
betaxolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- bisoprolol
bisoprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- bumetanide
potassium acid phosphate increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- canagliflozin
potassium acid phosphate and canagliflozin both increase serum potassium. Modify Therapy/Monitor Closely.
- candesartan
candesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- captopril
captopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- carbenoxolone
potassium acid phosphate increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- carvedilol
carvedilol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- celecoxib
celecoxib and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- celiprolol
celiprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- chlorothiazide
potassium acid phosphate increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- chlorthalidone
potassium acid phosphate increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- choline magnesium trisalicylate
choline magnesium trisalicylate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- cyclopenthiazide
potassium acid phosphate increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- diclofenac
diclofenac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- diflunisal
diflunisal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- digoxin
potassium acid phosphate and digoxin both increase serum potassium. Modify Therapy/Monitor Closely.
- disopyramide
potassium acid phosphate increases effects of disopyramide by pharmacodynamic synergism. Use Caution/Monitor. Additive cardiovascular depression.
- dobutamine
potassium acid phosphate increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- dopexamine
potassium acid phosphate increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- enalapril
enalapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- ephedrine
potassium acid phosphate increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- epinephrine
potassium acid phosphate increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- epinephrine racemic
potassium acid phosphate increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- eprosartan
eprosartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- esmolol
esmolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- ethacrynic acid
potassium acid phosphate increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- etodolac
etodolac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- fenoprofen
fenoprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- finerenone
potassium acid phosphate and finerenone both increase serum potassium. Modify Therapy/Monitor Closely. Finerenone dose adjustment based on current serum potassium concentration. Monitor serum potassium and adjust finerenone dose as described in the prescribing information as necessary.
- flurbiprofen
flurbiprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- formoterol
potassium acid phosphate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- fosinopril
fosinopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- furosemide
potassium acid phosphate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- gentamicin
potassium acid phosphate increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- hydrochlorothiazide
potassium acid phosphate increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- ibuprofen
ibuprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- ibuprofen IV
ibuprofen IV and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- imidapril
imidapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- indapamide
potassium acid phosphate increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- indomethacin
indomethacin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- irbesartan
irbesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- isoproterenol
potassium acid phosphate increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- ketoprofen
ketoprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- ketorolac
ketorolac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- ketorolac intranasal
ketorolac intranasal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- labetalol
labetalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- levalbuterol
potassium acid phosphate increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- lisinopril
lisinopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- lornoxicam
lornoxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- losartan
losartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- meclofenamate
meclofenamate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- mefenamic acid
mefenamic acid and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- meloxicam
meloxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- metaproterenol
potassium acid phosphate increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- methyclothiazide
potassium acid phosphate increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely. .
- metolazone
potassium acid phosphate increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- metoprolol
metoprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- moexipril
moexipril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- nabumetone
nabumetone and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- nadolol
nadolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- naproxen
naproxen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- nebivolol
nebivolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- noni juice
potassium acid phosphate and noni juice both increase serum potassium. Use Caution/Monitor.
- norepinephrine
potassium acid phosphate increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- olmesartan
olmesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- oxaprozin
oxaprozin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- parecoxib
parecoxib and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- penbutolol
penbutolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- perindopril
perindopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- pindolol
pindolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- pirbuterol
potassium acid phosphate increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- piroxicam
piroxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- potassium citrate/citric acid
potassium acid phosphate and potassium citrate/citric acid both increase serum potassium. Use Caution/Monitor.
- propranolol
propranolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- quinapril
quinapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- ramipril
ramipril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- sacubitril/valsartan
sacubitril/valsartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- salicylates (non-asa)
salicylates (non-asa) and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- salmeterol
potassium acid phosphate increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- salsalate
salsalate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- sotalol
sotalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- succinylcholine
potassium acid phosphate and succinylcholine both increase serum potassium. Modify Therapy/Monitor Closely.
- sulfasalazine
sulfasalazine and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- sulindac
sulindac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- telmisartan
telmisartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- terbutaline
potassium acid phosphate increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- timolol
timolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- tolfenamic acid
tolfenamic acid and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- tolmetin
tolmetin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
- tolvaptan
potassium acid phosphate and tolvaptan both increase serum potassium. Modify Therapy/Monitor Closely.
- torsemide
potassium acid phosphate increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- trandolapril
trandolapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.
- trimethoprim
trimethoprim and potassium acid phosphate both increase serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.
- valsartan
valsartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
- voclosporin
voclosporin and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.
Minor (29)
- acarbose
potassium acid phosphate increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- amphotericin B deoxycholate
amphotericin B deoxycholate decreases levels of potassium acid phosphate by increasing renal clearance. Minor/Significance Unknown.
- bisacodyl
bisacodyl decreases levels of potassium acid phosphate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- bisacodyl rectal
bisacodyl rectal decreases levels of potassium acid phosphate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- cadexomer iodine
cadexomer iodine increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.
- chlorpropamide
potassium acid phosphate increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- glimepiride
potassium acid phosphate increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- glipizide
potassium acid phosphate increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- glyburide
potassium acid phosphate increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- insulin aspart
potassium acid phosphate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- insulin detemir
potassium acid phosphate increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- insulin glargine
potassium acid phosphate increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- insulin glulisine
potassium acid phosphate increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- insulin lispro
potassium acid phosphate increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- insulin NPH
potassium acid phosphate increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- insulin regular human
potassium acid phosphate increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- iodinated glycerol
iodinated glycerol increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.
- iodine
iodine increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.
- metformin
potassium acid phosphate increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- miglitol
potassium acid phosphate increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- nateglinide
potassium acid phosphate increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- pioglitazone
potassium acid phosphate increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- repaglinide
potassium acid phosphate increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- rosiglitazone
potassium acid phosphate increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- saxagliptin
potassium acid phosphate increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- sitagliptin
potassium acid phosphate increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- tolazamide
potassium acid phosphate increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- tolbutamide
potassium acid phosphate increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
- vildagliptin
potassium acid phosphate increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.
Adverse Effects
Frequency Not Defined
Diarrhea
Nausea/vomiting
Stomach pain
Flatulence
Bradycardia
Hyperkalemia
Local tissue necrosis with extravasation
Weakness
Dyspnea
Hypocalcemia
Tetany
Phosphate intoxication
Hypotension
Arrhythmia
Warnings
Contraindications
Hyperphosphatemia, severe renal impairment, hyperkalemia, infected phophate stones
Cautions
May cause hyperkalemia; use caution in patients who require regulation of serum potassium concentrations
Patients may experience mild laxative effects within first few days of therapy
Use caution in patients with severe adrenal insufficiency, cardiac disease, myotonia congenita, pancreatitis, parathyroid disease, renal calculi, renal impairment, tissue breakdowns (burns), or rickets
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Use with caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Intracellular cation essential in physiological processes including transmission of nerve impulses, glucose utilization, muscle contractions, and enzyme activity
Acidifies urine
Pharmacokinetics
Distribution: Enters cells from extracellular fluid via active transport
Absorption: Well absorbed from upper GI tract
Excretion: Urine (primarily); skin and feces (small amount)
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
